Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients : the Swiss HIV Cohort Study

Swiss, HIV Cohort Study

doi:10.1111/j.1468-1293.2010.00885.x

Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients : the Swiss HIV Cohort Study

Date Issued

2011-01-01

Author(s)

Young, J

Scherrer, A U

Günthard, H F

Opravil, M

Yerly, S

Böni, J

Rickenbach, M

Fux, C A

Cavassini, M

Bernasconi, E

Vernazza, P

Hirschel, B

Battegay, M

Bucher, H C

Swiss, HIV Cohort Study

DOI

10.1111/j.1468-1293.2010.00885.x

Abstract

Darunavir was designed for activity against HIV resistant to other protease inhibitors (PIs). We assessed the efficacy, tolerability and risk factors for virological failure of darunavir for treatment-experienced patients seen in clinical practice.